JP2016516774A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516774A5
JP2016516774A5 JP2016507609A JP2016507609A JP2016516774A5 JP 2016516774 A5 JP2016516774 A5 JP 2016516774A5 JP 2016507609 A JP2016507609 A JP 2016507609A JP 2016507609 A JP2016507609 A JP 2016507609A JP 2016516774 A5 JP2016516774 A5 JP 2016516774A5
Authority
JP
Japan
Prior art keywords
composition according
composition
light
bioactive agent
wavelength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016507609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516774A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033337 external-priority patent/WO2014168950A1/en
Publication of JP2016516774A publication Critical patent/JP2016516774A/ja
Publication of JP2016516774A5 publication Critical patent/JP2016516774A5/ja
Withdrawn legal-status Critical Current

Links

JP2016507609A 2013-04-08 2014-04-08 光応答性化合物 Withdrawn JP2016516774A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809695P 2013-04-08 2013-04-08
US61/809,695 2013-04-08
PCT/US2014/033337 WO2014168950A1 (en) 2013-04-08 2014-04-08 Photo-responsive compounds

Publications (2)

Publication Number Publication Date
JP2016516774A JP2016516774A (ja) 2016-06-09
JP2016516774A5 true JP2016516774A5 (enExample) 2017-06-01

Family

ID=51689955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507609A Withdrawn JP2016516774A (ja) 2013-04-08 2014-04-08 光応答性化合物

Country Status (5)

Country Link
US (1) US20160144031A1 (enExample)
EP (1) EP2983677A4 (enExample)
JP (1) JP2016516774A (enExample)
CN (1) CN105307663A (enExample)
WO (1) WO2014168950A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
ES2743458T5 (es) 2014-08-08 2023-06-08 Us Health Eliminación fotocontrolada de dianas in vitro e in vivo
EP3331909A1 (en) 2015-08-07 2018-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer
EP3827846B1 (en) 2015-08-18 2024-10-02 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
CN114699525A (zh) 2015-08-18 2022-07-05 乐天医药生技股份有限公司 酞菁染料偶联物的制造方法及稳定偶联物
WO2020113130A1 (en) * 2018-11-29 2020-06-04 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
WO2020252297A1 (en) * 2019-06-14 2020-12-17 The University Of North Carolina At Chapel Hill Photoactive compositions for therapuetic agent delivery
CN110215179B (zh) * 2019-06-20 2022-02-25 京东方科技集团股份有限公司 胶囊内窥镜的释药装置及胶囊内窥镜
CN112168977A (zh) * 2020-10-27 2021-01-05 西南大学 转铁蛋白修饰的二氧化硅荷载白藜芦醇及制备方法和应用
CN114216982B (zh) * 2021-12-14 2024-08-09 黑龙江飞鹤乳业有限公司 维生素b12的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007533B1 (en) * 1996-08-27 2005-06-22 University Of Utah Research Foundation Bioconjugates and delivery of bioactive agents
US8076318B2 (en) * 2002-10-24 2011-12-13 Albert Einstein College Of Medicine Of Yeshiva University Caged ligands and uses thereof
EP1565714A4 (en) * 2002-11-18 2009-06-03 Panomics Inc ORDERING uncaging
ATE459725T1 (de) * 2002-11-18 2010-03-15 Panomics Inc Caged-sensoren, -regulatoren und-verbindungen sowie verwendungen davon
US7759459B2 (en) * 2003-01-10 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Fluorescent assays for protein kinases
US9744236B2 (en) * 2009-06-26 2017-08-29 The Trustees Of Columbia University In The City Of New York Photolabile compounds

Similar Documents

Publication Publication Date Title
JP2016516774A5 (enExample)
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2008000180A1 (es) Sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)fenil]ciclobutanocarboxamida; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como depresion, trastornos del sueno, ansiedad y enfermedades del tracto
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
BR112015023333A8 (pt) pirrolbenzodiazepinas e conjugados dos mesmos
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
JP2015525757A5 (enExample)
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
BRPI0922771A2 (pt) agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
GT201400069A (es) Composiciones farmaceuticas
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
JP2015532296A5 (enExample)
IL200044A (en) Tricyclic compounds as modulators of a glucocorticoid receptor and their use in the preparation of drugs for the treatment of diseases
SI1940409T1 (sl) Nove zdravilske kombinacije za zdravljenje bolezni dihalnih poti
ES2550461T3 (es) Uso de S-adenosilmetionina (SAM) y superóxido dismutasa (SOD) para la preparación de medicamentos para el tratamiento de la enfermedad de Alzheimer
CL2008003232A1 (es) Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
CL2008000804A1 (es) Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible.
EA200900923A1 (ru) Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний
JP2018508589A5 (enExample)